BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] plunged by -$0.95 during the normal trading session on Thursday and reaching a high of $12.01 during the day while it closed the day at $10.92. The company report on March 2, 2021 that BioCryst Submits Marketing Authorization Application for UK Approval of ORLADEYO™ (berotralstat), an Oral, Once-daily Therapy to Prevent Attacks in Patients with Hereditary Angioedema.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the company has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) seeking approval of ORLADEYO™ (berotralstat) for the prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. The MAA was submitted under the MHRA’s new European Commission Decision Reliance Procedure (ECDRP).
On February 25, 2021, BioCryst announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion recommending the approval of ORLADEYO for routine prevention of recurrent attacks of HAE in adult and adolescent patients aged 12 years and older. The European Commission (EC) will review the CHMP recommendation and a final approval decision from the EC on the marketing authorization application for ORLADEYO is expected in the second quarter.
BioCryst Pharmaceuticals Inc. stock has also gained 4.30% of its value over the past 7 days. However, BCRX stock has inclined by 124.23% in the 3 months of the year. Over the past six months meanwhile, it has gained 177.86% and gained 46.58% year-on date.
The market cap for BCRX stock reached $1.87 billion, with 176.52 million shares outstanding and 175.06 million shares in the current float. Compared to the average trading volume of 8.40M shares, BCRX reached a trading volume of 8167443 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $13.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 1.00, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 35.00. The Price to Book ratio for the last quarter was 57.47, with the Price to Cash per share for the same quarter was set at 0.84.
BCRX stock trade performance evaluation
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.30. With this latest performance, BCRX shares gained by 3.70% in over the last four-week period, additionally plugging by 177.86% over the last 6 months – not to mention a rise of 211.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 53.66, with the RSI for the last a single of trading hit 50.42, and the three-weeks RSI is set at 55.62 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 9.31, while it was recorded at 11.46 for the last single week of trading, and 5.74 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -981.12 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -137.94, given the latest momentum, and Return on Invested Capital for the company is -171.32. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.76, with Total Debt to Total Assets ending up at 44.74.
Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.50.
Earnings per share (EPS) analysis for BioCryst Pharmaceuticals Inc. [BCRX] stock
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX]: Insider Ownership positions
There are presently around $1,318 million, or 70.10% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,259,745, which is approximately 1.981% of the company’s market cap and around 0.70% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,695,818 shares of the stock with an approximate value of $138.64 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $126.67 million in BCRX stock with ownership of nearly 1.013% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 98 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 19,662,631 shares. Additionally, 70 investors decreased positions by around 25,378,182 shares, while 23 investors held positions by with 75,628,723 shares. The mentioned changes placed institutional holdings at 120,669,536 shares, according to the latest SEC report filing. BCRX stock had 39 new institutional investments in for a total of 7,054,392 shares, while 16 institutional investors sold positions of 2,953,720 shares during the same period.